

Acute Liver Failure Unmasking XIAP-Deficiency in Very Early Onset IBD

Alyssa Baccarella MD¹, Tamir Diamond MD¹, Aaron Bennett MD¹, Trusha Patel, MD¹, Brooke Boyer, MD¹, Maire Conrad, MD¹, Hana Conlon CRNP², Whitney Petrosa CRNP², Kathleen M. Loomes MD¹, Scott Canna MD^{2,3}, Judith R. Kelsen, MD¹

¹ Division of Gastroenterology, Hepatology, and Nutrition; Children's Hospital of Philadelphia, ² Immune Dysregulation Program; Children's Hospital of Philadelphia,

³ Division of Rheumatology; Children's Hospital of Philadelphia

INTRODUCTION

- XIAP deficiency has a broad spectrum of manifestations, including HLH, IBD, uveitis, and episodic fevers
- VEO-IBD may be the presenting symptom of many inborn errors of immunity (IEI) and intestinal epithelial cell defects
- Liver manifestations of XIAP have rarely been reported
- Here we describe a case of severe acute liver failure in a patient with VEO-IBD, found to have XIAP deficiency

PATIENT PRESENTATION

- Age 5: presented with hematochezia, perianal skin tags, intermittent fevers
- Age 6: diagnosed with VEO-IBD - endoscopic and histologic colitis and granulomas
- Age 6: IFX 10mg/kg with achievement of clinical remission
- Age 8: presented with fever, hepatitis, cholestasis, and abdominal pain, EBV IgM+
- 5 days later: Progressive cholestasis, rising transaminases, new synthetic dysfunction, hepatic encephalopathy.
- Admitted to tertiary care facility ICU, listed for liver transplant
- Initial labs with moderately elevated sIL2R, IFN gamma, ferritin, possible evolving HLH (Table 1)
- Treated with methylprednisolone and emapalumab with improvement (Figure 1)
- XIAP flow revealed absence of XIAP expression (Figure 2)

Infectious Workup	EBV IgM weak +, EBV IgG, Hep A/B immune, negative EBV, CMV, adenovirus, HHV6, HSV, HIV PCRs, negative toxoplasmosis, negative strongylides, negative TB testing, negative blood cultures
Autoimmune/Metabolic	ANA 1:80, anti-F-actin weak +, normal LKM and anti-smooth muscle, normal ceruloplasmin, normal metabolic screens
Immune	Normal DHR, low NK cells (52), mildly elevated IgE (87) ANC 1620, Hgb 9.2, plt 177 Ferritin 290, fibrinogen 103, triglycerides 162 sIL2R 1500, IFNG 128 IL6 7.6, IL8 86, IL10 10, TNFa 4.7, IL-18 12,000 Normal protein/granzyme

Table 1: Select labs at time of presentation




Figure 1: Transaminase and inflammatory marker trends (top), synthetic dysfunction (middle), and fever curve (bottom)

RESULTS




Figure 2: Diagnostic flow cytometry showing absence of XIAP expression in major lineages (courtesy of Cincinnati Diagnostic Immunology Lab)




Figure 3: Liver biopsy (D17 post-admission) (A) H&E staining showing periportal and centrilobular collapse, hepatocellular injury (B) Reticulin staining highlighting hepatocellular cord collapse (C) Trichrome staining without fibrosis (D) CK7 staining showing regeneration of bile ducts

REFERENCES

- 1.Mudde ACA, Booth C, Marsh RA. Evolution of Our Understanding of XIAP Deficiency. *Front Pediatr.* 2021 Jun 17;9:660520. doi: 10.3389/fped.2021.660520. PMID: 34222142; PMCID: PMC8247594. Kollarz D, et al. Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy. *Nat Genet.* 2018 Mar;50(3):344–348. doi: 10.1038/ng.2018.1063. Epub 2018 Feb 26. PMID: 29483653; PMCID: PMC630986
- 2.Kelsen JR, Baldassano RN. The role of monogenic disease in children with very early onset inflammatory bowel disease. *Curr Opin Pediatr.* 2017 Oct;29(5):566–571. doi: 10.1097/MOP.0000000000000531. PMID: 28700415; PMCID: PMC5642912.
- 3.Pacholnuk Schmidt J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, Kanegane H, Lopez-Granados E, Mejstrikova E, Peller I, Galicier L, Galambraun C, Barlogis V, Bordigoni P, Fourmaux A, Hamidou M, Dabade A, Le Deist F, Haerynk F, Ouachée-Chardin M, Rohrlich P, Stephan JL, Lenoir C, Rigaud S, Lambert N, Milli M, Schiff C, Chapel H, Picard C, de Saint Basile G, Blanche S, Fischer A, Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAPI deficiency). *Blood.* 2011 Feb 3;117(5):1522–9. doi: 10.1182/blood-2010-07-298372. Epub 2010 Nov 30. PMID: 21119115

MANAGEMENT AND OUTCOMES

- Targeted sequencing confirmed an XIAP frameshift variant (c.1021_1022del, p.(N341Yfs*8))
- Anakinra started
- Liver biopsy: mild inflammation, hepatocellular injury without fibrosis, and regenerating bile ducts (Figure 3)
- Liver function and mental status improved, transitioned to ruxolitinib pre-discharge while awaiting HSCT
- Underwent mismatched unrelated donor transplant with pre-phase emapalumab and conditioned with campath, fludarabine, thiotepa, and melphalan.

DISCUSSION

- Acute liver failure is a rare manifestation of XIAP deficiency
- Antecedent EBV infection likely triggered this case of liver failure
- High suspicion for underlying IEI/immune dysregulation should be considered in cases of acute liver failure and VEO-IBD
- HSCT can be curative in XIAP-deficiency, and should be considered in cases of intestinal inflammation and severe manifestations such as liver failure

ACKNOWLEDGEMENTS

This work was funded by NIDDK K23 DK119585 (MAC), R01 DK111843 (JRK), and R01DK127044-02 (JRK). Thank you to Dr. Benjamin J. Wilkins for pathology slides and interpretation, and Cincinnati Diagnostic Immunology Lab for flow cytometry based diagnostic testing